Meeting Banner
Abstract #0017

Predictive Value of Myo-inositol Measured by MRSI during Anti-angiogenic Treatment in Recurrent Glioblastoma

Michael Wenke1, Jorg Dietrich2, Elizabeth Gerstner2, Otto Rapalino3, Julian He3, Daniel Kim1, Melanie Fu1, Pratik Talati4, Mohamed El Abtah1, Anna Vaynrub1, Sharif Natheir1, Mark Vangel3, Isabel Arrillaga-Romany2, Forst Deborah2, Yi-Fen Yen1, Ovidiu Andronesi1, Jayashree Kalpathy-Cramer1, Tracy Batchelor5, Bruce Rosen1, R. Gilberto Gonzalez3, and Eva-Maria Ratai1
1Radiology / Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States, 2Neurology / Cancer Center, Massachusetts General Hospital, Boston, MA, United States, 3Radiology, Massachusetts General Hospital, Boston, MA, United States, 4Neurosurgery, Massachusetts General Hospital, Boston, MA, United States, 5Neurology, Brigham and Women's Hospital, Boston, MA, United States

Patients with recurrent glioblastoma (rGBM) are commonly treated with anti-angiogenic agents such as bevacizumab (BEV), but not all benefit from this therapy. We examined whether MR spectroscopic imaging (MRSI) of myo-inositol (mI) could distinguish short-term survivors from longer term survivors (>9 month). We scanned twenty-two rGBM patients with MRSI at baseline prior to bevacizumab-based therapy, as well as 1-2 days, 4 weeks, 6-8 weeks and 16 weeks after treatment. We found that low tumoral myo-inositol normalized by creatine (Cr) on the contralateral site (mI/c-Cr) prior to and during anti-angiogenic therapy is predictive of poor survival.

This abstract and the presentation materials are available to members only; a login is required.

Join Here